5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates

ACSM Certified Clinical Exercise Physiologist ACSM-CEP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy

2 Applied Exercise Physiology & Metabolic Calculations

Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold

3 Pathophysiology of Clinical Populations

3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)

4 Clinical ECG Interpretation

4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

5 Pharmacology for the Clinical Exercise Physiologist

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing

6 Patient Assessment (Domain I, 18%)

6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status

7 Clinical Exercise Testing (Domain II, 18%)

Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)

8 Exercise Prescription for Clinical Populations (Domain III, 22%)

FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription

9 Exercise Training & Leadership (Domain IV, 24%)

9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination

10 Education & Behavior Change (Domain V, 13%)

10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support

11 Legal, Professional & Emergency Management (Domain VI, 5%)

11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates

Key Takeaways Explain This Topic AI

Beta-blockers blunt the heart-rate response to exercise and lower maximal achievable heart rate, so RPE (Borg 6–20) should guide intensity instead of estimated %HRmax or heart-rate-reserve targets.

Non-dihydropyridine calcium-channel blockers (verapamil, diltiazem) also blunt heart rate similarly to beta-blockers; combining the two raises the risk of excessive bradycardia or AV block.

Dihydropyridine calcium-channel blockers (amlodipine, nifedipine) are primarily vasodilators that can cause reflex tachycardia and peripheral edema, with minimal direct heart-rate effect.

Nitrates raise the ischemic threshold by reducing cardiac preload, but risk hypotension and reflex tachycardia; combining nitrates with a PDE-5 inhibitor is an absolute contraindication.

A true measured peak heart rate from a symptom-limited graded exercise test performed on the patient's usual medication is more accurate than an age-predicted formula for any rate-limiting drug.

Last updated: July 2026

Beta-Blockers, Calcium-Channel Blockers & Nitrates

Quick Answer: Beta-blockers and non-dihydropyridine calcium-channel blockers (verapamil, diltiazem) blunt the heart-rate response to exercise, so target heart rate ranges must be reset using RPE or a medicated graded exercise test. Dihydropyridine calcium-channel blockers and nitrates are primarily vasodilators — their biggest exercise risk is hypotension, not a blunted heart rate.

Cardiovascular medications rarely appear on a patient's chart in isolation, and three of the most common classes — beta-blockers , calcium-channel blockers (CCBs) , and nitrates — each change how the clinical exercise physiologist (CEP) reads heart rate, blood pressure, and symptoms during testing and training. Getting these effects right is a patient-safety issue: using an unadjusted heart-rate target on a beta-blocked patient can produce an exercise prescription that is either dangerously hard or uselessly easy. Because these three classes are frequently prescribed together — for example, a post-myocardial-infarction patient may be on a beta-blocker, a statin, and a nitrate simultaneously — the CEP must separate which observed hemodynamic response belongs to which drug before drawing any conclusion about a patient's true exercise capacity or safety status.

Beta-Blockers

Beta-blockers (metoprolol, atenolol, and bisoprolol are cardioselective ; propranolol, carvedilol, and labetalol are nonselective and also affect beta-2 and, for carvedilol/labetalol, alpha-1 receptors) block sympathetic stimulation of the heart. The result is a lower resting heart rate, a blunted heart-rate response across the entire exercise-intensity spectrum , and a reduced maximal heart rate — which means age-predicted formulas (220 − age) and standard percent-HRmax or heart-rate-reserve targets calculated from an estimated HRmax are no longer valid.

Exam-critical implication: the preferred way to guide intensity in a beta-blocked patient is Rating of Perceived Exertion (RPE) on the Borg 6–20 scale — RPE tracks workload more reliably than heart rate under beta-blockade. Where a precise heart-rate-based prescription is still needed, the CEP should use the actual measured peak heart rate from a symptom-limited graded exercise test performed while the patient is on their usual beta-blocker dose , not an estimate.

Other exam-relevant effects: fatigue and reduced exercise tolerance are common complaints; beta-blockers can blunt the adrenergic warning signs of hypoglycemia (tachycardia, tremor) in patients also taking insulin or a sulfonylurea, so those patients need to be taught to recognize other cues such as sweating or confusion; and nonselective agents can provoke bronchospasm , warranting caution in patients with asthma or COPD.

Calcium-Channel Blockers

CCBs split into two functionally different subclasses:

Dihydropyridines (amlodipine, nifedipine, felodipine) act mainly on vascular smooth muscle as potent vasodilators. They have little direct effect on heart rate, though reflex tachycardia , flushing, headache, and peripheral edema can occur as the body responds to the drop in vascular resistance.

Non-dihydropyridines (verapamil, diltiazem) are rate-limiting: they blunt both AV conduction (negative dromotropic effect) and heart rate (negative chronotropic effect) at rest and during exercise, similarly to beta-blockers, and are often prescribed specifically for rate control in atrial fibrillation. Combining a non-dihydropyridine with a beta-blocker raises the risk of excessive bradycardia or AV block and should be flagged during medication reconciliation.

Both subclasses share one common exercise risk: exercise-associated or post-exercise hypotension from vasodilation, so extended cool-down monitoring is warranted.

Nitrates

Nitroglycerin (sublingual tablet or spray, used acutely) and isosorbide mono/dinitrate (longer-acting, used prophylactically) treat angina by causing venous — and to a lesser extent arterial — vasodilation. This reduces cardiac preload and afterload, lowering myocardial oxygen demand and raising the ischemic threshold , so a patient may be able to exercise to a meaningfully higher workload before angina or ischemic ECG changes appear, especially if a prophylactic dose was taken before the session per physician instructions.

The trade-off is hypotension and reflex tachycardia , including orthostatic hypotension after dosing — have the patient seated or supine if symptomatic. One absolute safety flag for chart review: nitrates must never be combined with a PDE-5 inhibitor (sildenafil, tadalafil) — the combination can cause severe, life-threatening hypotension and should be escalated to the referring physician immediately if discovered.

Drug Class vs. Exercise Response

Drug Class Resting HR Exercise HR BP Effect Key Exercise Consideration

Beta-blockers (metoprolol, carvedilol) Decreased Blunted; lower HRmax Decreased Use RPE, not %HRmax/HRR from an estimated HRmax

Non-DHP CCBs (verapamil, diltiazem) Decreased Blunted Decreased Similar HR-blunting; caution combined with beta-blockers

DHP CCBs (amlodipine, nifedipine) Unchanged/reflex increase Unchanged/reflex increase Decreased (vasodilation) Watch for exercise hypotension, peripheral edema

Nitrates (nitroglycerin, isosorbide) Unchanged/reflex increase Largely unchanged Decreased Raises angina threshold; orthostatic hypotension; never with PDE-5 inhibitors

Recognizing which class a patient is taking — and which physiologic signal it alters — is what separates a safe, individualized exercise prescription from one built on invalid assumptions about heart rate. When a chart lists more than one of these classes together, work through each one individually before combining their expected effects, since a blunted heart rate from a beta-blocker and a vasodilation-driven hypotension risk from a nitrate call for two different monitoring strategies during the same session.